ClinicalTrials.gg
Drug

Homoharringtonine clinical trials

Also written Homoharringtonine, omacetaxine mepesuccinate and CGX-635.

studies test it
40
open now
13
in phase 3
7
first study started
1994

How each study uses Homoharringtonine is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the Homoharringtonine studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
26 Oct 2012 · SYNRIBO · NDA 203585 (FDA, Drugs@FDA)
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Synribo
7
HHT
5
OMA
2
Omacetaxine Mepesuccinate Injection
2
Cytarabine
2

Development codes

Homoharringtonine
25
CGX-635
6

Other names

omacetaxine mepesuccinate
10
Omacetaxine
9

Studies by the year they started

39 studies that test it; most in 2024 (6)

Studies that test Homoharringtonine, by start year
YearStudies
19941
19981
19992
20001
20051
20061
20071
20081
20111
20132
20142
20152
20161
20172
20181
20191
20201
20223
20231
20246
20254
20263

By phase

A phase 1/2 study counts in both.

Early Phase 1
1
Phase 1
8
Phase 2
26
Phase 3
7
No phase
4

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 6 · Other 34

Institute of Hematology & Blood Diseases Hospital, China (5) · Teva Branded Pharmaceutical Products R&D, Inc. (4) · M.D. Anderson Cancer Center (4) · National Cancer Institute (NCI) (4) · First Affiliated Hospital of Zhejiang University (2) · The University of Hong Kong (2) · ChemGenex Pharmaceuticals (2) · Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine (2)

Often tested with

Tested in the same studies.

Cytarabine (9) · Venetoclax (8) · Azacitidine (7) · Decitabine (4) · Idarubicin (3) · Mitoxantrone (3) · Granulocyte Colony-Stimulating Factor (3) · Antiandrogen Therapy (2)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 2

Studies that test Homoharringtonine.

Studies

Open first, then newest update. How each study uses Homoharringtonine is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 40

See all 40 studies that test Homoharringtonine →

Given beside what is tested · 11 — Homoharringtonine is usual care or a partner of the new treatment
As the comparator · 1 — what is tested is compared with Homoharringtonine

Codes

What other systems call Homoharringtonine · ClinicalTrials.gg INT006810

  • MeSH (NLM) D000077863HomoharringtonineConfirmed ClinicalTrials.gov, NLM
  • UNII (FDA) 6FG8041S5BOMACETAXINE MEPESUCCINATEConfirmed FDA, NLM, Wikidata
  • RxNorm 27100Confirmed FDA, Wikidata
  • Wikidata Q7089373(-)-homoharringtonineConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C1127Omacetaxine MepesuccinateConfirmed FDA, Wikidata
  • DrugBank DB04865One source Wikidata

Also registered as omacetaxine (UNII 84MI6OYN4Z · RxNorm 1546446).

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.